3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one

We are 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one CAS: 503615-03-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one
CAS.NO: 503615-03-0
Synonyms:5-morpholin-4-yl-1-(4-nitrophenyl)-2,3-dihydropyridin-6-one
2(1H)-Pyridinone, 5,6-dihydro-3-(4-morpholinyl)-1-(4-nitrophenyl)-

Molecular Formula:C15H17N3O4
Molecular Weight: 303.31300

Physical and Chemical Properties:
Density:1.4±0.1 g/cm3
Boiling point:506.5±50.0 °C at 760 mmHg
Melting point: /
Flash point: 260.1±30.1 °C
Refractive index: 1.625

Specification:
Appearance: Yellow powder
Purity: 98%
LC/MS:Conformity with the structure
NMR:Conformity with the structure
Water:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Application:Intermediates of Apixaban CAS:503612-47-3

 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one


Related News: The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.4635-59-0 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”6980-08-1 Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.2-(Chloromethyl)-1-fluoro-4-(trifluoromethyl)benzene Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.

Related Products
Product Name
Azetidine hydrochloride View Details
4-Bromo-3-fluorobenzotrifluoride View Details
2-Chloro-5-hydroxypyridine View Details
2-Fluoro-5-methylbenzaldehyde manufacturer 2-Amino-4-fluoropyridine manufacturer Ethyl linoleate (JAN) manufacturer Phenyltrichlorosilane manufacturer 1-FLUORO-4-IODOBUTANE manufacturer